Captor Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $38.0Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2025-06-01attributed |
| Founded | 2015 |
| Headquarters | Wroclaw, Poland |
| Industry | biotech |
| Stage | unknown |
| Website | captortherapeutics.com |
Captor Therapeutics develops small-molecule drugs using targeted protein degradation to hit disease targets that conventional drugs cannot reach. It aims to treat patients with cancer and autoimmune diseases who lack good options. Its Optigrade platform pairs protein engineering, structural biology, and molecular modeling, making it one of the first European companies built on targeted protein degradation, listed on the Warsaw Stock Exchange.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-06-01 | grant | $2.7M | undisclosed |
Detected tech stack
Nginx, UIKit, Reddit, particles.js, Python
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $38.0M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | captortherapeutics.com, read 2026-05-02 |
| Description | self-reported | captortherapeutics.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.